DeCure for Biliary tract neoplasm

Biliary tract neoplasm is described as one of the most aggressive malignancies with a very poor prognosis. Most cancers have grown beyond the limits of curative resection by the time they become clinically evident. Only one third of patients can undergo radical surgery; the remainder present with unresectable, locally advanced, or metastatic disease. Among the drugs tested, gemcitabine has the best efficacy-toxicity ratio, but efficacy results remain disappointing. The combination of gemcitabine and cisplatin significantly prolongs survival and is the standard treatment for locally advanced or metastatic biliary tract cancer. The gemcitabine-oxaliplatin combination is described as one of the most promising schedules.

A retrospective analysis of 186 consecutive patients with unresectable biliary tract cancer treated with chemotherapy between 2000 and 2009 at five Japanese institutions found that prognosis has improved recently. Patients were divided into three groups by treatment era: Group A (2000–2003), Group B (2004–2006), and Group C (2007–2009). In Group A, 5-fluorouracil-based chemotherapies were primarily selected as first-line, and only 24% received second-line chemotherapy. In Group B, gemcitabine or S-1 monotherapy was mainly introduced as first-line, and 51% received second-line monotherapy. In Group C, combination therapy with gemcitabine and S-1 was mainly chosen as first-line, and 53% received second-line combination therapy. The median time to progression was 4.4 months in Group A, 3.5 months in Group B, and 5.9 months in Group C (P < 0.01). Median overall survival was 7.1 months, 7.3 months, and 11.7 months in Groups A, B, and C respectively (P = 0.03). Induction rates of all three drugs (gemcitabine, platinum analogs, and fluoropyrimidine) were 4%, 2%, and 27% across the groups (P < 0.01). The authors concluded that using three effective drugs may improve prognosis.

Advances in imaging over the five years prior to 2004 allowed for earlier diagnosis and better surgical planning. CT scan and ultrasound are the mainstay radiological modalities for staging biliary tract malignancy, assessing response to non-surgical treatment, detecting recurrence after resection, and follow-up. Palliative management of obstructive disease was improved with the advent of photodynamic therapy. Biological studies evaluating mutation-independent activation of the Hedgehog pathway have provided information on carcinogenesis and opportunities for future targeted therapies. A 2025 clinical case report describes the use of anti-HER2 therapy in a patient with advanced intrahepatic cholangiocarcinoma, using both standard cytostatics and modern targeted drugs.

What is still missing are large, prospective trials that can confirm whether the sequential or combination use of gemcitabine, platinum analogs, and fluoropyrimidine genuinely improves survival beyond the modest gains seen in retrospective data. Patient stratification by molecular markers such as Hedgehog pathway activation or HER2 status is not yet standard, and the rarity of the disease makes recruitment for such trials difficult. Funding for biomarker-driven studies and for randomised comparisons of targeted agents against standard chemotherapy remains insufficient.